Back

Long term outcome of unprotected left main coronary artery disease : comparison between CABG and pci in korean single center

25 August 2018 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 4 - Coronary interventions : outcomes Outcome ESC Premium Access ESC Congress 2018

About the speaker

Photo
Doctor Kai Song

Busan (Korea (Republic of))

9 More presentations in this session

Presentation thumbnail
Outcomes following percutaneous coronary intervention in Non-ST-segment elevation myocardial infarction patients with previous coronary artery bypass grafts surgery
Doctor A. shoaib (Stoke-on-Trent, GB)
Abstract
Presentation thumbnail
Comparison of 3 year outcomes between medical therapy and percutaneous revascularisation for surgically ineligible patients.
Doctor A. Ekmejian (Wollongong, AU)
Abstract Slides
Presentation thumbnail
Patients with prior CABG treated with primary PCI have high long-term adverse outcome: an observational study of 26,799 patients with STEMI from the London heart attack group
Doctor K. Rathod (London, GB)
Abstract Slides
Presentation thumbnail
Gender difference in long-term clinical outcomes after rotational atherectomy in severely calcified coronary stenoses - From J2T multicenter registry
Associate Professor H. Otsuki (Tokyo, JP)
Abstract
Presentation thumbnail
Outcomes of percutaneous coronary intervention in native vessels versus bypass grafts in prior coronary artery bypass graft patients: a meta-analysis
Professor B. Zhang (Dalian, CN)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 4 - Coronary interventions : outcomes

The Event

Event poster

ESC Congress 2018

25 August - 29 August 2018
You may be interested in
thumbnail
Congress Presentation
Percutaneous intervention is better than surgery in real life for most patients: pro
thumbnail
Congress Presentation
Association of PCI with outcomes in stable coronary artery disease
thumbnail
Congress Presentation
Prognostic impact of intravascular imaging in percutaneous coronary intervention according to atherothrombotic risk

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources